Please use this identifier to cite or link to this item:
Title: Pharmacogenetics of VKORC1 in warfarin resistant patients.
Authors: Ong, Jacqueline Kai Mei.
Keywords: DRNTU::Science::Biological sciences::Microbiology::Drug Resistance
Issue Date: 2010
Abstract: Warfarin is a commonly prescribed anticoagulant that displays wide inter-individual variability in treatment response and dosage. It acts by inhibiting the vitamin K epoxide reductase (VKOR) enzyme in the liver. Genetic variations in vitamin K epoxide reductase complex subunit 1(VKORC1), have been associated with differential dose requirement of warfarin. However, high variability in treatment response is still observed. The hypothesis is that other functional polymorphisms in VKORC1 may influence the enzymatic activity of VKOR, leading to variation in the pharmacodynamics of warfarin. Thus, the aim of this study is to investigate novel polymorphisms in VKORC1 that may influence the activity of VKOR in patients receiving varying warfarin dosages. In this study, the VKORC1 gene was screened for novel polymorphisms in 32 subjects. A total of fifteen mutations were found, of which eight were novel. In particular, 337 G>A, 1849_1850 insertion T and 4851 T>G were found to be present in higher frequencies in the high-dose patients. This exploratory study provides the basis for future studies of the pharmacogenetics of VKORC1 in a larger population.
Rights: Nanyang Technological University
Fulltext Permission: restricted
Fulltext Availability: With Fulltext
Appears in Collections:SBS Student Reports (FYP/IA/PA/PI)

Files in This Item:
File Description SizeFormat 
SBS 10-021.pdf
  Restricted Access
462.67 kBAdobe PDFView/Open

Page view(s) 50

Updated on Jun 24, 2022


Updated on Jun 24, 2022

Google ScholarTM


Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.